Friday, 29 October 2021

Australia's most trusted
source of pharma news

Friday, 29 October 2021

GSK wins praise in Covid fight

 Posted 23 September 2021 PM

GSK's newly approved monoclonal antibody treatment Xevudy has been singled out for praise at a parliamentary hearing, which was told it's time for Australia to have "cautious optimisim" thanks not just to vaccines - but the development in Covid treatments.

Associate Professor Nick Coatsworth, who has been the federal government's public face in the fight against the pandemic, told the Senate Select hearing into COVID-19 that in his role as Executive Director of Medical Services at Canberra Hospital he spent time on the wards and had seen the drug in action.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read. If you don't have a password, just enter your email address and then click Login.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.